We invest between £0.25 – 10 million
in fast growing businesses
Achilles Therapeutics is designing therapies to target truncal tumour neo-antigens which were first discovered by Cancer Research UK and the NIHR University College London Hospitals (UCLH) Biomedical Research Centre (BRC) funded scientists at the Francis Crick Institute and UCL Cancer Institute.
The project repurposes a sophisticated antibody engineering approach, to research and develop a new treatment against Covid-19. Existing research used in the fight against cancer is being applied to create a unique ‘cocktail’ of recombinant antibodies capable of preventing the virus from entering cells and removing it from circulation.
AstronauTx Ltd is a biotech company developing new medicines designed to restore the normal behaviour of astrocytes for the treatment of Alzheimer’s disease and other neurodegenerative diseases.
Using the latest machine learning techniques and human intelligence to detect astroturfing campaigns at 'Tweet Zero'.
The Bloomsbury AI team joined the London Team of Facebook.
Bramble Energy has developed technology capable of producing gigawatts of hydrogen fuel cells using existing global manufacturing resources, dramatically reducing the time to market and investment needed versus existing fuel cell designs.
Echopoint Medical Ltd is developing a family of optical-fibre based sensors which integrate into medical innovative devices: bringing unparalleled sensing modalities to minimally-invasive procedures.
Epsilogen (formerly known as IGEM) is an innovative immuno-oncology company targeting cancer with the IgE class of antibodies, which have evolved to kill tissue-dwelling multicellular parasites and exhibit several key features that make it ideal for treating solid tumours
Freeline Therapeutics is a biopharmaceutical company focused on the development of liver-directed gene therapies. Freeline went on to IPO on Nasdaq in August 2020.
Hazy automates the process of anonymizing data for companies that hold vast swathes of customer information.
Humanloop’s technology enables AI systems to query human experts on only the most valuable data and learn much faster.
MeiraGTx is a vertically integrated, clinical stage gene therapy company. It has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. IPO on Nasdaq in 2018.
Nozzle have developed an AI powered platform that unifies large datasets and automatically optimises sales performance for marketplace sellers.
Odin Vision is developing the next generation of AI enabled applications for endoscopic procedures.
Orchard Therapeutics is a biotechnology company dedicated to bringing transformative gene therapies to patients with serious and life-threatening orphan diseases. It is a spin-out from the Institute of Child Health (ICH) at UCL. IPO on Nasdaq in 2018
Leading academics at UCL and University of Bristol with expertise in the fields of computer science, experimental and theoretical physics, and maths have joined forces to create PhaseCraft.
Quell has been established with the aim of developing engineered T regulatory cell therapies. Quell will seek to utilise the power of Treg cells to advance therapies for the management and treatment of a range of solid organ transplant and autoimmune conditions.
Third Space Learning (formerly known as Matr) provides one-to-one tutoring services via a proprietary online platform and aims to connect lower cost, higher quality tutoring supply from developing countries to developed economies.
We back risk-takers and change-makers. Founders with a vision and the determination to make it happen.
AlbionVC is the technology investment arm of Albion Capital Group LLP, which is authorised and regulated by the Financial Conduct Authority.
Registered in England No. OC341254 Registered Office: 1 Benjamin St, Farringdon, London, EC1M 5QL. Member of the British Venture Capital Association